Biocon Limited has officially informed stock exchanges regarding a significant name change within its subsidiary structure. Biosimilar Collaborations Ireland Limited, a subsidiary of Biocon Biologics Limited (BBL), has been renamed to Biocon Biologics Ireland Limited. This change was formally effective starting March 27, 2026, following information received by the parent company on March 29, 2026. The disclosure adheres to regulatory filing requirements.
Corporate Update on Subsidiary Restructuring
Biocon Limited issued a formal intimation to the BSE Limited and the National Stock Exchange of India Limited regarding a modification concerning one of its material step-down subsidiaries. This announcement was released on March 30, 2026.
Details of the Name Change
The core of the announcement pertains to the subsidiary of Biocon Biologics Limited (BBL), referred to as one of the material subsidiaries of Biocon. The subsidiary previously known as Biosimilar Collaborations Ireland Limited has undergone a statutory name change.
The new, officially adopted name is Biocon Biologics Ireland Limited. This name change took effect retroactively from March 27, 2026, as confirmed by information relayed to Biocon on March 29, 2026.
Compliance and Disclosure
The company confirmed that the full details of this corporate action are available for public review on the official company website, www.biocon.com. The filing was executed by Rajesh U. Shanoy, Company Secretary and Compliance Officer, under Scrip Code 532523 (BSE) and Scrip Symbol BIOCON (NSE).
Source: BSE
